L-Homocysteic acid (Synonyms: L-HCA) |
Catalog No.GC66843 |
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC50: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14857-77-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC50: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders[1][2][3].
L-Homocysteic acid activates NMDA receptor with an EC50 value of 14 μM[1].
L-Homocysteic acid (100 μM) induces large currents (1.8 nA) that is insensitive to the NMDA receptor-antagonist mixture in Purkinje cells[1].
L-Homocysteic acid (250 μM, 30 min) potently induces an acute excitotoxic reaction in ex vivo chick embryo retina[2].
L-Homocysteic acid (0-2 mM, 48 h) induces a concentration-dependent neurotoxic effect in rat primary neurons[3].
L-Homocysteic acid (intraperitoneal injection, 4-11 mmol/kg) elicits seizures in rats during early postnatal development[4].
L-Homocysteic acid (intraperitoneal injection, 100-1500 mg/kg) partially substitutes for NMDA, producing maximum values of 61-67% NMDA-lever responding at doses of 1000 and 560 mg/kg, respectively in Sprague-Dawley rats[5].
Animal Model: | Male albino rats of the Wistar strain[4] |
Dosage: | 4, 5.5, 8, 11 mM/kg |
Administration: | Intraperitoneal injection, daily for 14 days |
Result: | Induced flexion seizures at 4 mmol/kg. Led to intense tail flicking, pivoting, and locomotion. Decreased ECoG (electrocorticograms) activity for 5-9 min. |
[1]. M Yuzaki, et al. Characterization of L-homocysteate-induced currents in Purkinje cells from wild-type and NMDA receptor knockout mice. J Neurophysiol . 1999 Nov;82(5):2820-6.
[2]. J W Olney, et al. L-homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. Brain Res Bull. 1987 Nov;19(5):597-602.
[3]. B Lockhart, et al. Inhibition of L-homocysteic acid and buthionine sulphoximine-mediated neurotoxicity in rat embryonic neuronal cultures with alpha-lipoic acid enantiomers. Brain Res. 2000 Feb 14;855(2):292-7.
[4]. P Mares, et al. Convulsant action of D,L-homocysteic acid and its stereoisomers in immature rats.
[5]. Katherine L Nicholson, et al. The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats. Psychopharmacology (Berl). 2009 Apr;203(2):441-51.
Cas No. | 14857-77-3 | SDF | Download SDF |
Synonyms | L-HCA | ||
Formula | C4H9NO5S | M.Wt | 183.18 |
Solubility | Storage | Store at -20°C | |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.4591 mL | 27.2956 mL | 54.5911 mL |
5 mM | 1.0918 mL | 5.4591 mL | 10.9182 mL |
10 mM | 0.5459 mL | 2.7296 mL | 5.4591 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *